Applied Genetic Technologies (AGTC) Misses Q4 EPS by 20c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Applied Genetic Technologies (AGTC) Misses Q4 EPS by 20c, Revenues Miss

AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018

September 10, 2018 4:03 PM EDT

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the fourth quarter and fiscal year ended June 30, 2018.

We have achieved significant progress across our broad and diverse portfolio of five ophthalmology development programs, said Sue Washer, President and CEO of AGTC. We expanded our clinical and medical leadership teams, maintained a robust balance sheet and ended our fiscal... More